David Neff

David Neff

Auto-generated profile, based on publicly available information

David Neff

Merck, Sharp & Dohme Corp, Whitehouse Station, New Jersey

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Vascular Health and Risk Management
Verified
Journal Article
Open access
EMElizabeth Marrett
Elizabeth Marrett
CZChanggeng Zhao
Changgeng Zhao
NZNing Jackie Zhang
Ning Jackie Zhang
QZQiaoyi Zhang
Qiaoyi Zhang
DRDena Ramey
Dena Ramey
DNDavid Neff
David Neff
Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes. Atorvastatin is a common statin with greater LDL-C lowering efficacy than most other statins; its availability in generic form will likely increase its use. This study assessed attainment of guideline-recommended LDL-C levels in high-risk CVD patients treated with atorvastatin monotherapy. Analyses of two retrospective US cohorts of patients who received a prescription for atorvastatin monotherapy between January 1, 2008 and December 31, 2010 (index date defined as first prescription date) in the GE Centricity Electronic Medical Record (EMR) (N=10,693) and Humana Medicare (N=16,798) databases. Eligible patients were ≥18 years, diagnosed with coronary heart disease or atherosclerotic vascular disease, with ≥1 LDL-C measurement between 3 months and 1 year postindex date, and continuously enrolled for 1 year prior to and following the index date. Of the eligible patients, 21.8%, 29.6%, 29.9%, and 18.7% (GE Centricity EMR) and 25.4%, 32.9%, 27.8%, and 14.0% (Humana Medicare) received 10, 20, 40, and 80 mg doses of atorvastatin, respectively. The mean ± standard deviation (SD) follow-up LDL-C levels were 2.1±0.8 mmol/L (83±30 mg/dL) and 2.3±0.8 mmol/L (88±31 mg/dL) for the GE Centricity EMR and Humana Medicare cohorts, respectively. Regardless of dose, only 28.3%-34.8% of patients had LDL-C levels 1.8 mmol/L (>70 mg/dL), and of these, 30%-40% had LDL-C levels ≥0.5 mmol/L (≥20 mg/dL) above this, regardless of dose. This suggests that more effective lipid-lowering strategies, such as statin uptitration, switching to a higher efficacy statin, and/or combination therapy, may be required to achieve optimal LDL-C lowering in high-risk patients.

1 May 2014 in Clinical Therapeutics
Verified
Journal Article
Closed access
VAVeronica Ashton
Veronica Ashton
QZQiaoyi Zhang
Qiaoyi Zhang
NZNing Jackie Zhang
Ning Jackie Zhang
CZChanggeng Zhao
Changgeng Zhao
DRDena Rosen Ramey
Dena Rosen Ramey
EMElizabeth Marrett
Elizabeth Marrett

1 May 2012 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
NLNgoc-Anh Le
Ngoc-Anh Le
MFMonica Farkas-Epperson
Monica Farkas-Epperson
RRan Jin
Ran Jin
ATAndrew M. Tershakovec
Andrew M. Tershakovec
DNDavid R. Neff
David R. Neff
PWPeter Wilson
Peter Wilson

1 May 2012 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
NLNgoc-Anh Le
Ngoc-Anh Le
RRan Jin
Ran Jin
ATAndrew M. Tershakovec
Andrew M. Tershakovec
DNDavid R. Neff
David R. Neff
JTJoanne E. Tomassini
Joanne E. Tomassini
PWPeter Wilson
Peter Wilson

1 May 2013 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
EMElizabeth Marrett
Elizabeth Marrett
CZChanggeng Zhao
Changgeng Zhao
NZNing Jackie Zhang
Ning Jackie Zhang
QZQiaoyi Zhang
Qiaoyi Zhang
DRDena Ramey
Dena Ramey
DNDavid Neff
David Neff